bezlotoxumab
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract Background The incidence of Clostridioides difficile infection (CDI) is reportedly higher and the cure rate lower in…
Bezlotoxumab is a fully human monoclonal antibody that binds and neutralizes Clostridium difficile toxin B. This analysis…
The MODIFY I/II trials demonstrated that bezlotoxumab, a human monoclonal antibody against Clostridioides difficile toxin B…
Das Darmbakterium Clostridioides difficile ist eine der häufigsten Ursachen nosokomialer Diarrhöen. Die C.-difficile-Infektion…
Clostridium difficile infection (CDI) is a leading nosocomial disease estimated to cause nearly half a million cases in the…
OBJECTIVE
To review the pharmacology, pharmacokinetics, pharmacodynamics, clinical efficacy, tolerability, dosing, and…
ABSTRACT Introduction: Clostridium difficile infection is a major economic and clinical burden, due to its high frequency of…
Abstract Background CDI in patients with SRI is harder to treat and is associated with higher recurrence. MODIFY I/II found that…
Background . Treatment guidelines recommend stopping CAs in patients with Clostridium dif fi cile infection (CDI), but this is not…